Ciprofol versus propofol for blood pressure during general anesthesia in stroke clot removal
Compares ciprofol with propofol for blood pressure control in adults having stroke clot removal.
Plain-language title generated from the registry record
Registry title: Ciprofol vs Propofol for Hemodynamic Stability in Patients Having General Anesthesia for Endovascular Thrombectomy After Ischemic Stroke
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults having a stroke caused by a blocked brain artery who need a clot-removal procedure under general anesthesia. It compares two anesthetic drugs, ciprofol and propofol.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Acute ischemic stroke, with no bleeding in the brain on CT or MRI scan, and an NIHSS score of 2 or higher.
Main reasons for not taking part
- Severe problems from earlier neurological damage (mRS 3-5)
- Shock
- Severe heart disease
- Contraindications to EVT per AHA guidelines
- Taking part in another conflicting clinical trial
Read by machine on 9 November 2026.
Where in China
- Shanghai Jiaotong University School of MedicineShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- RenJi Hospital
- Trial code
- NCT07696208
- Record updated
- 10 July 2026
- Original description
Endovascular therapy (EVT) improves the prognosis of patients with acute ischemic stroke (AIS). EVT has been established as a standard of care for AIS caused with large vessel occlusion based on numerous randomized controlled trials. However, despite extensive attention to post-EVT blood pressure management as a potentially modifiable factor, the ability to achieve high reperfusion rates does not consistently translate into functional independence for a substantial number of patients. Thus, the focus has turned to the intra-procedural period, where blood pressure management may play a critical but underexamined role in determining functional outcomes independent of post-EVT care.Read full original descriptionShow less
Ciprofol vs Propofol for Hemodynamic Stability in Patients Having General Anesthesia for Endovascular Thrombectomy After Ischemic Stroke: A Multicenter Randomized Open-label Parallel-group Trial (CONSTANCY)
Endovascular therapy (EVT) improves the prognosis of patients with acute ischemic stroke (AIS). EVT has been established as a standard of care for AIS caused with large vessel occlusion based on numerous randomized controlled trials. However, despite extensive attention to post-EVT blood pressure management as a potentially modifiable factor, the ability to achieve high reperfusion rates does not consistently translate into functional independence for a substantial number of patients. Thus, the focus has turned to the intra-procedural period, where blood pressure management may play a critical but underexamined role in determining functional outcomes independent of post-EVT care.
Guideline recommendation to maintain the blood pressure lowered to 185/110 mmHg before the EVT procedure in patients who have not received intravenous thrombolysis therapy. However, studies of blood pressure before reperfusion in this patient group have produced conflicting results. Thus, although randomized trials evaluating pre-thrombectomy blood pressure targets are yet unavailable, accumulating evidence suggests that active blood pressure lowering before reperfusion may be harmful, which underscores the importance of maintaining hemodynamic stability during the EVT procedure.
In this context, anesthetic management is a key determinant of intraprocedural blood pressure control. Propofol is the most commonly used general anesthetic during EVT surgery. However, propofol is a powerful venodilator and often provokes hypotension which may be especially detrimental in AIS patients. Ciprofol, a novel anesthetic/sedative, has been proven to possess excellent efficacy and safety which provides definitive general anesthesia/sedation while minimizing respiratory and hemodynamic depression. Before and during EVT, patients with hemodynamic stability may have better outcomes. Using ciprofol as the anesthesia agent may reduce the incidence and severity of hemodynamic instability during EVT. Therefore, it is of significant research value to investigate whether the use of ciprofol for general anesthesia is beneficial in AIS patients undergoing EVT.
Inclusion: Age ≥18 years; Clinical diagnosis of AIS; CT/MRI-confirmed absence of intracranial hemorrhage; Eligible for EVT; NIHSS score ≥2; ASA physical status I-III; Signed informed consent.
Exclusion: Severe cardiac disease; Pre-existing severe neurological deficits (mRS 3-5); Shock; Contraindications to EVT per AHA guidelines; Participation in conflicting clinical trials.